Donald H. Maurice, Ph.D
- Telephone: 613-533-6000 x75089
- E-Mail: email@example.com
Faculty BioThe Maurice Lab is interested in investigating the role of cyclic nucleotide (cAMP and cGMP) compartmentation and cyclic nucleotide signaling in human vascular cells including arterial endothelial cells and arterial smooth muscle cells. Since virtually all cells are either directly or indirectly influenced by cAMP and or cGMP, this system represents a potential therapeutic target in multiple cardiovascular diseases such as atherosclerosis and restenosis, and is important processes such as angiogenesis.
Our laboratory investigates how signal compartmentation allows cAMP to regulate simultaneously myriad cellular events with specificity. Overall, our work shows that Cyclic Nucleotide Phosphodiesterase (PDEs), the sole enzymes that inactivate cAMP by hydrolysis, are critical for specificity in this system. In addition, while our studies demonstrate that PDEs are highly “druggable”, they also identify critical shortcoming in current targeting approaches. Specifically, although humans can generate >100 unique PDE variants, and PDEs are known to operate within unique cAMP signaling compartments in cells, current therapeutic strategies have failed to capitalize on their highly compartmented actions. Indeed, most approaches focus on findings agents that inhibit selected PDE activities by catalytic site inhibition without considering the hyper-localized nature of their actions (review Maurice et al., Nature Reviews, Drug Discovery, 13:290, 2014)1. The research elaborated here is a comprehensive plan to identify strategies that will allow inhibition of PDEs in their “natural environment” (i.e. in compartments) and to begin to translate these strategies into approaches to limit the mal-adaptive consequences of atherosclerosis and angiogenesis.Further information available at MauriceLab.com
Last Modified: 2017-10-10